Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia,Leukemia

当前位置： X-MOL 学术 › Leukemia › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia
Leukemia ( IF 12.8 ) Pub Date : , DOI: 10.1038/leu.2017.276
S Degryse , C E de Bock , S Demeyer , I Govaerts , S Bornschein , D Verbeke , K Jacobs , S Binos , D A Skerrett-Byrne , H C Murray , N M Verrills , P Van Vlierberghe , J Cools , M D Dun

Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia

Leukemia, Published online: 30 August 2017; doi:10.1038/leu.2017.276

中文翻译：